ClinicalTrials.gg
CompletedNCT02557100Updated Sep 3, 2020Results posted

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

A Phase 4 interventional study of Abatacept and Adalimumab in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 28 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-03.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
75th of 113
80 · median 130
Started
2015
with 7 others
Phase 4
38 of 113
3 open now
Registered
85th of 113
by date
Lead sponsor
6 of 113
Bristol-Myers Squibb

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 75th largest by enrollment, is one of 8 that started in 2015, is one of 38 in phase 4, and was the 85th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to examine changes in immune cells and proteins in response to treatment with two approved therapies for Rheumatoid arthritis (RA), abatacept versus adalimumab, both given in combination with methotrexate.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Symptoms of RA for no more than 12 months prior to enrollment
  • Meet American College of Rheumatology/European League against Rheumatism (ACR/EULAR) 2010 criteria for classification of RA
  • Treated with Methotrexate (MTX) for at least 12 weeks prior to randomization with a stable oral dose for at least 4 weeks, Subjects must randomize on the maximum tolerated dose of oral methotrexate (minimum of 15 mg and maximum of 25 mg per week), dose of MTX \< 15 mg/week but ≥ 7.5 mg/week is permitted if subjects are intolerant to higher doses
  • At least 3 tender \& 3 swollen joints
  • Anti-cyclic citrullinated peptide (CCP) > 3X the and positive rheumatoid factor

Exclusion criteria

Exclusion Criteria:

  • History of other diseases (eg, psoriasis, systemic lupus, erythematosus, etc)
  • Prior use of non-biologic therapy other than methotrexate
  • Prior use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARD) therapy
  • Subjects with chronic or recent acute serious infection

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Treatment A

    Abatacept Single Blind Treatment Period

    Drug: Abatacept · Drug: Methotrexate

  • Active comparator
    Treatment B

    Adalimumab Single Blind Treatment Period

    Drug: Abatacept · Drug: Adalimumab · Drug: Methotrexate

  • Active comparator
    Treatment C

    Abatacept Cumulative Treatment Period

    Drug: Abatacept

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Adverse Events (AEs)

    Percentage of participants who experienced an AE

    Time frame: up to 85 days post last dose, approximately 40 weeks

  2. Percentage of Participants With an Serious Adverse Events (SAEs)

    Percentage of participants who experienced an SAEs

    Time frame: up to 85 days post last dose, approximately 40 weeks

  3. Percentage of Participants With Adverse Events Leading to Discontinuation (AEsDc)

    Percentage of participants who experienced an (AEsDc)

    Time frame: up to 85 days post last dose, approximately 40 weeks

  4. Percentage of Serious Adverse Events Leading to Discontinuation (SAEsDc)

    Percentage of participants who experienced an (SAEsDc)

    Time frame: up to 85 days post last dose, approximately 40 weeks

  5. Percentage of Drug Related Adverse Events (DRAEs)

    Percentage of participants who experienced an DRAEs

    Time frame: up to 85 days post last dose, approximately 40 weeks

  6. Percentage of Drug Related Serious Adverse Events (DRSAEs)

    Percentage of participants who experienced an DRSAEs

    Time frame: up to 85 days post last dose, approximately 40 weeks

  7. Number of Deaths

    Number of participants who experienced Death

    Time frame: up to 85 days post last dose, approximately 40 weeks

07

Results

Posted Sep 3, 2020

Participant flow

Single Blind Treatment Period
Participant flow — Single Blind Treatment Period
MilestoneTreatment ATreatment BTreatment C
Started40400
Completed40360
Not completed040
Withdrew: Lost to follow-up010
Withdrew: Death010
Withdrew: Request to discontinue010
Withdrew: Adverse event010
Transition to Open Label
Participant flow — Transition to Open Label
MilestoneTreatment ATreatment BTreatment C
Started40360
Completed000
Not completed40360
Withdrew: Entered cumulative abatacept period40360
Cumulative Abatacept Period
Participant flow — Cumulative Abatacept Period
MilestoneTreatment ATreatment BTreatment C
Started0076
Completed0072
Not completed004
Withdrew: Other reasons001
Withdrew: Lost to follow-up002
Withdrew: Request to discontinue001

Outcome measures

PrimaryPercentage of Adverse Events (AEs)

Percentage of participants who experienced an AE

Time frame:
up to 85 days post last dose, approximately 40 weeks
Reported as:
Number · Percentage of participant with AEs
Percentage of Adverse Events (AEs)
Percentage of participant with AEsTreatment ATreatment BTreatment C
Percentage of Adverse Events (AEs)55.070.057.9
PrimaryPercentage of Participants With an Serious Adverse Events (SAEs)

Percentage of participants who experienced an SAEs

Time frame:
up to 85 days post last dose, approximately 40 weeks
Reported as:
Number · Percentage of participants with SAEs
Percentage of Participants With an Serious Adverse Events (SAEs)
Percentage of participants with SAEsTreatment ATreatment BTreatment C
Percentage of Participants With an Serious Adverse Events (SAEs)2.55.05.3
PrimaryPercentage of Participants With Adverse Events Leading to Discontinuation (AEsDc)

Percentage of participants who experienced an (AEsDc)

Time frame:
up to 85 days post last dose, approximately 40 weeks
Reported as:
Number · Percentage of participants with AEsDC
Percentage of Participants With Adverse Events Leading to Discontinuation (AEsDc)
Percentage of participants with AEsDCTreatment ATreatment BTreatment C
Percentage of Participants With Adverse Events Leading to Discontinuation (AEsDc)02.50
PrimaryPercentage of Serious Adverse Events Leading to Discontinuation (SAEsDc)

Percentage of participants who experienced an (SAEsDc)

Time frame:
up to 85 days post last dose, approximately 40 weeks
Reported as:
Number · Percentage of participants with SAEsDc
Percentage of Serious Adverse Events Leading to Discontinuation (SAEsDc)
Percentage of participants with SAEsDcTreatment ATreatment BTreatment C
Percentage of Serious Adverse Events Leading to Discontinuation (SAEsDc)02.50
PrimaryPercentage of Drug Related Adverse Events (DRAEs)

Percentage of participants who experienced an DRAEs

Time frame:
up to 85 days post last dose, approximately 40 weeks
Reported as:
Number · Percentage of participants with DRAEs
Percentage of Drug Related Adverse Events (DRAEs)
Percentage of participants with DRAEsTreatment ATreatment BTreatment C
Percentage of Drug Related Adverse Events (DRAEs)30.027.522.4
PrimaryPercentage of Drug Related Serious Adverse Events (DRSAEs)

Percentage of participants who experienced an DRSAEs

Time frame:
up to 85 days post last dose, approximately 40 weeks
Reported as:
Number · Percentage of Participants with DRSAEs
Percentage of Drug Related Serious Adverse Events (DRSAEs)
Percentage of Participants with DRSAEsTreatment ATreatment BTreatment C
Percentage of Drug Related Serious Adverse Events (DRSAEs)02.50
PrimaryNumber of Deaths

Number of participants who experienced Death

Time frame:
up to 85 days post last dose, approximately 40 weeks
Reported as:
Number · Number of Deaths
Number of Deaths
Number of DeathsTreatment ATreatment BTreatment C
Number of Deaths010

Adverse events

Collected over up to 85 days post last dose, approximately 40 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/40 (0%)1/40 (2.5%)21/40 (52.5%)
Treatment B1/40 (2.5%)2/40 (5%)28/40 (70%)
Treatment C0/76 (0%)4/76 (5.3%)19/76 (25%)
Most frequent serious events
Most frequent serious events
EventTreatment ATreatment BTreatment C
Atrial Septal DefectCongenital, familial and genetic disorders1/400/401/76
Sudden DeathGeneral disorders0/401/400/76
VaricellaInfections and infestations0/401/400/76
Cerebral InfarctionNervous system disorders1/400/401/76
Incision site complicationInjury, poisoning and procedural complications0/400/401/76
Patella fractureInjury, poisoning and procedural complications0/400/401/76
Myocardial InfarctionCardiac disorders0/400/401/76
Most frequent other events
Most frequent other events
EventTreatment ATreatment BTreatment C
Upper respiratory tract infectionInfections and infestations3/4014/4010/76
Alanine Aminotransferase IncreasedInvestigations3/406/409/76
Aspartate Aminotransferase IncreasedInvestigations2/405/407/76
NasopharyngitisInfections and infestations4/402/405/76
Urinary Tract InfectionInfections and infestations4/400/405/76
AlopeciaSkin and subcutaneous tissue disorders1/403/400/76
Gamma-glutamyltransferase increasedInvestigations2/400/402/76
HeadacheNervous system disorders2/402/400/76
LeukopeniaBlood and lymphatic system disorders0/402/400/76
NeutropeniaBlood and lymphatic system disorders0/402/400/76

Baseline characteristics

All Participants treated in the single-blind period

Age, Continuous
Age, Continuous(Years)Treatment ATreatment BTreatment CTotal
Mean47.2 ± 12.1644.7 ± 16.30—46.0 ± 14.35
Sex: Female, Male
Sex: Female, Male(Participants)Treatment ATreatment BTreatment CTotal
Female2931—60
Male119—20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment ATreatment BTreatment CTotal
Hispanic or Latino46—10
Not Hispanic or Latino1614—30
Unknown or Not Reported2020—40
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment ATreatment BTreatment CTotal
American Indian or Alaska Native00—0
Asian02—2
Native Hawaiian or Other Pacific Islander00—0
Black or African American41—5
White3636—72
More than one race00—0
Unknown or Not Reported01—1
08

Study locations

28 sites
  • University Of Alabama At Birmingham
    Birmingham, Alabama 35294-7201, United States
  • Rheumatology Associates Of North Alabama, P.C.
    Huntsville, Alabama 35801, United States
  • Clinical And Translational Research Center Of Alabama, Pc
    Tuscaloosa, Alabama 35406, United States
  • Arizona Arthritis & Rheumatology Research PLLC
    Glendale, Arizona 85306, United States
  • Arizona Arthritis & Rheumatology Research PLLC
    Phoenix, Arizona 85037, United States
  • St. Joseph Heritage Medical Group
    Fullerton, California 92835, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • University Of Colorado Health Sciences Center
    Aurora, Colorado 80045, United States
  • Medical Faculty Associates,Inc.
    Washington, District of Columbia 20037, United States
  • Howard University Hospital
    Washington, District of Columbia 20060, United States
  • Integral Rheumatology & Immunology Specialists
    Plantation, Florida 33324, United States
  • Marietta Rheumatology
    Marietta, Georgia 30060, United States
  • The Center For Rheumatology And Bone Research
    Wheaton, Maryland 20902, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Aa Mrc Llc
    Grand Blanc, Michigan 48439, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Oregon Health & Science University (Ohsu)
    Portland, Oregon 97239, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635-8406, United States
  • Carolina Health Specialists
    Myrtle Beach, South Carolina 29572, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Arthritis Clinic Of Northern Virginia, P.C.
    Arlington, Virginia 22205, United States
  • Dr. Anil K Gupta Med Prof Corp
    Toronto, Ontario M9V 4B4, Canada
  • Essex County Medical Society
    Windsor, Ontario N8X 5A6, Canada
  • Institut De Rhumatologie De Montreal
    Montreal, Quebec H2L 1S6, Canada
  • Centre De Recherche Musculo-Squelettique
    Trois-rivieres, Quebec G8Z 1Y2, Canada
  • CINTRE - Centro de investigacion y tratamiento reumatologico, S.C.
    Mexico City, Distrito Federal 11850, Mexico
  • Clinica de Investigacion en Reumatologia y Obesidad S.C.
    Guadalajara, Jalisco 44650, Mexico
  • Clinica Integral en Osteoporosis y Artritis CLINOSAR Mexico S.A. de C.V.
    Mexico D.F., 06760, Mexico
09

References and documents

Publications

  • Rigby W, Buckner JH, Louis Bridges S Jr, Nys M, Gao S, Polinsky M, Ray N, Bykerk V. HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA. Arthritis Res Ther. 2021 Sep 18;23(1):245. doi: 10.1186/s13075-021-02607-7. PubMed 34537057 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Mar 2019, 40 months.

Results were first posted in Sep 2020, 1 year 5 months after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 40 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2015
First posted
Sep 23, 2015
StartActual
Nov 19, 2015
Primary completionActual
Mar 28, 2019
CompletionActual
Mar 28, 2019
Results first posted
Sep 3, 2020
Last update
Sep 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02557100
Responsible party
Sponsor
First posted
Sep 23, 2015
Start date
Nov 19, 2015
Primary completion
Mar 28, 2019
Completion
Mar 28, 2019
Results posted
Sep 3, 2020
Last update
Sep 3, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion